Abstracts tagged "registry and tocilizumab"

Abstract Number: 2437 • 2015 ACR/ARHP Annual Meeting
Experience with Tocilizumab for Treatment of 56 Children with Systemic Juvenile Idiopathic Arthritis in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Johannes Peter Haas³, Toni Hospach⁴, Ralf Trauzeddel⁵, Hans-Iko Huppertz⁶, J B. Kuemmerle-Deschner⁷, Kirsten Minden⁸ and BIKER Registry Study Group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁵HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁶PRINTO, IRCCS G. Gaslini, Genoa, Italy, ⁷Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁸DRFG, Berlin, Germany
Background/Purpose: Tocilizumab (TOC) has become a valuable option for treatment of systemic juvenile idiopathic arthritis (sJIA), which significantly improved the outcome of patients. The aim…
Abstract Number: 2296 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Therapy in Children with Systemic Juvenile Idiopathic Arthritis. DATA from Russian Register of Sjia
Ekaterina Alexeeva^1,2, Saniya Valieva¹, Rina Denisova¹, Tatyana Bzarova¹, Kseniya Isayeva¹, Tatyana Sleptsova¹, Elena Mitenko¹, Evgeniya Chistyakova^1,2, Anna Fetisova¹ and Olga Lomakina³, ¹Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ²I.M.Sechenov First Moscow State Medical University, Moscow, Russia, ³Scientific Center of Children's Health of RAMS, Moscow, Russia
Background/Purpose Systemic Juvenile Idiopathic Arthritis (sJIA) is classified as an acquired autoinflammatory disease. The interleukin-1 and interleukin-6 play a pivotal role in pathogenesis of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].